6 hours ago · Netherlands
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
What's happening
SignalsMonitor is following this as a markets story. The Guardian Business is the outlet attached so far. The reports are tied to Netherlands. The first report grouped here was at 10 Nov 2026, 13:00 UTC. The headline in use is “Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by The Guardian UK
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
Reported by 1 outlet
- The Guardian